HLB Pharmaceutical CEO Park Jae Hyung stake steady at 1.51% after rights offer

Common shares rose by 92,652 to 657,378 through a paid-in rights offering priced at KRW 5,650 per share. Warrants for 92,652 shares expired following the capital increase, leaving total voting shares unchanged.